Valneva SE (VALN)
VALN Stock Price Chart
Explore Valneva SE interactive price chart. Choose custom timeframes to analyze VALN price movements and trends.
VALN Company Profile
Discover essential business fundamentals and corporate details for Valneva SE (VALN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 May 2021
Employees
713.00
Website
https://valneva.comCEO
Thomas Lingelbach
Description
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.
VALN Financial Timeline
Browse a chronological timeline of Valneva SE corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.19, while revenue estimate is $44.14m.
Earnings released on 13 May 2026
EPS came in at -$0.42 falling short of the estimated -$0.21 by -100.00%, while revenue for the quarter reached $36.18m , missing expectations by -33.85%.
Earnings released on 16 Mar 2026
EPS came in at -$0.68 falling short of the estimated -$0.17 by -293.06%, while revenue for the quarter reached $55.88m , beating expectations by +6.52%.
Earnings released on 20 Nov 2025
EPS came in at -$0.61 falling short of the estimated -$0.30 by -103.33%, while revenue for the quarter reached $34.45m , missing expectations by -29.49%.
Earnings released on 12 Aug 2025
EPS came in at -$0.16 surpassing the estimated -$0.27 by +40.74%, while revenue for the quarter reached $56.91m , beating expectations by +45.54%.
Earnings released on 7 May 2025
EPS came in at -$0.13 surpassing the estimated -$0.31 by +58.06%, while revenue for the quarter reached $53.97m , beating expectations by +21.32%.
Earnings released on 20 Mar 2025
EPS came in at -$0.54 falling short of the estimated -$0.22 by -145.45%, while revenue for the quarter reached $54.82m , beating expectations by +49.38%.
Earnings released on 7 Nov 2024
EPS came in at -$0.15 surpassing the estimated -$0.30 by +50.00%, while revenue for the quarter reached $50.26m , missing expectations by -10.08%.
Earnings released on 13 Aug 2024
EPS came in at -$0.37 surpassing the estimated -$0.39 by +5.13%, while revenue for the quarter reached $40.92m , missing expectations by -9.26%.
Earnings released on 7 May 2024
EPS came in at $0.89 surpassing the estimated $0.77 by +15.58%, while revenue for the quarter reached $35.19m , missing expectations by -2.25%.
Earnings released on 20 Mar 2024
EPS came in at -$0.50 falling short of the estimated $0.20 by -350.00%, while revenue for the quarter reached $46.08m , missing expectations by -40.01%.
Earnings released on 9 Nov 2023
EPS came in at -$0.54 falling short of the estimated -$0.51 by -5.88%, while revenue for the quarter reached $40.16m , missing expectations by -10.90%.
Earnings released on 21 Sept 2023
EPS came in at -$0.26 surpassing the estimated -$0.36 by +27.78%, while revenue for the quarter reached $43.89m , beating expectations by +27.37%.
Earnings released on 4 May 2023
EPS came in at -$0.28 surpassing the estimated -$0.35 by +20.00%, while revenue for the quarter reached $36.43m , beating expectations by +10.04%.
Earnings released on 23 Mar 2023
EPS came in at -$0.65 falling short of the estimated $0.29 by -324.14%, while revenue for the quarter reached $120.00m , missing expectations by -24.18%.
Earnings released on 10 Nov 2022
EPS came in at $1.33 surpassing the estimated -$0.14 by +1.05k%, while revenue for the quarter reached $153.01m , beating expectations by +32.02%.
Earnings released on 11 Aug 2022
EPS came in at -$2.86 falling short of the estimated -$1.32 by -116.67%, while revenue for the quarter reached $74.66m , missing expectations by -8.89%.
Earnings released on 5 May 2022
EPS came in at -$0.54 surpassing the estimated -$0.92 by +41.30%, while revenue for the quarter reached $24.17m , beating expectations by +5.44%.
Earnings released on 24 Mar 2022
EPS came in at $2.03 surpassing the estimated $0.33 by +515.15%, while revenue for the quarter reached $157.72m , missing expectations by -9.56%.
Earnings released on 18 Nov 2021
EPS came in at -$1.85 falling short of the estimated $1.68 by -210.34%, while revenue for the quarter reached $25.94m , beating expectations by +2.56%.
Earnings released on 10 Aug 2021
EPS came in at -$1.22 falling short of the estimated -$0.58 by -110.34%, while revenue for the quarter reached $28.81m , beating expectations by +18.64%.
VALN Stock Performance
Access detailed VALN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
